Apoptosis is mediated through at least three major pathways that are regulated by (i) the death receptors, (ii) the mitochondria and (iii) the ER (endoplasmic reticulum). In most cells, these pathways are controlled by the Bcl-2 family of proteins that can be divided into anti-apoptotic and pro-apoptotic members. Although the overall amino acid sequence homology between the family members is relatively low, they contain highly conserved domains, referred to as BH (Bcl-2 homology) domains (BH1-4), that are essential for homo-and hetero-complex formation, as well as for their cell-death-inducing capacity. Structural and functional analyses revealed that the pro-apoptotic homologues can be subdivided into the Bax subfamily and the growing BH3-only subfamily. Recent data indicate that BH3-only proteins act as mediators that link various upstream signals, including death receptors and DNA damage signalling, to the mitochondrial and the ER pathway. This review discusses recent structural and functional insights into how these subfamilies promote or inhibit cell-death signals, and how these properties may be utilized for development of apoptosis-promoting small molecules, e.g. in cancer therapy.
Introduction
Members of the bcl-2 (the B-cell lymphoma gene 2) gene family play a key role as sensors and gatekeepers that control the execution machinery of apoptosis. Like the cysteinyl aspartases (caspases) that mediate the initiation and execution of apoptosis, the evolutionary origins of the constituents of the apoptosome, a key regulatory protein complex that mediates cell death through the mitochondrial pathway, can be traced back to Caenorhabditis elegans and Drosophila.
The importance of Bcl-2 and related molcules becomes obvious when the phenotypes of mutant animals are analysed. Targeted gene-knockout of the bcl-2 gene in mice results in the occurrence of grey hair, polycystic kidney disease and lymphocytopenia. In contrast, homozygous disruption of the bcl-2-homologous bcl-x gene is lethal during embryonic development and coincides with massive apoptosis in postmitotic immature neurons of brain and spinal cord and in the haematopoietic system. Analyses of mice carrying only one disrupted bcl-x allele showed that lymphocyte maturation was disturbed. The life-span of immature lymphocytes, but not mature lymphocytes, was shortened. Thus, Bcl-x functions to support the viability of immature cells during the development of the nervous and haematopoietic systems. Knockout of the pro-apoptotic bcl-2-homologous bax gene (see below) in mice results in a milder phenotype, including hyperplasia of non-neuronal lineages, such as lymphocytes and ovarian granulosa cells, and testicular degeneration. In the nervous system, Bax is required for neuronal death after deprivation of neurotrophic factors. Interestingly, loss of Bax [1] or high expression of Bcl-2 [2] facilitates tumorigenesis. Thus deregulation of Bcl-2 homologues and consecutive resistance to apoptosis appears to be a critical event in oncogenic transformation.
Recent studies have provided novel and quite unexpected insights into the mechanisms by which Bcl-2 family proteins might issue life permits or death sentences in cells. Nevertheless, we are still on the way to fully understanding their modes of action. This review compiles recent developments regarding the structural and functional regulation of these proteins and how we may exploit our knowledge of this family of proteins to fight diseases such as cancer or autoimmunity, where loss of apoptosis control is critically involved in pathogenesis.
Bcl-2 and its homologues were gained when it was recognized that mitochondria play a critical role in apoptosis, whether the extrinsic, deathreceptor-mediated, or the intrinsic apoptosis pathway is triggered, e.g. upon nuclear stress (Figure 1 ). Upon activation during apoptosis, they release proteins such as cytochrome c, Smac (second mitochondrial activator of
Figure 1. Bcl-2 proteins regulate the intrinsic and extrinsic apoptosis pathways
The extrinsic apoptosis pathway (left) is induced by death receptor ligands, such as the CD95/Fas ligand (CD95L). A death-inducing signalling complex consisting of CD95L, the CD95 receptor, the adapter protein FADD and pro-caspase-8 is formed at the cell membrane, leading to activation of the initiator caspase-8. Caspase-8 in turn cleaves and activates the effector caspase-3. In contrast, the intrinsic death receptor-independent pathway (right) is triggered by the majority of apoptotic stimuli, including cytotoxic drugs, ceramide and irradiation, and leads to the loss of the mitochondrial membrane potential and release of cytochrome c and other pro-apoptotic factors (see text) into the cytosol. Bcl-2 inhibits, whereas pro-apoptotic Bcl-2 homologues, such as Bax or Bak, promote release of these pro-apoptotic factors. Cytochrome c, together with (d)ATP, Apaf-1 and pro-caspase-9, then forms the mitochondrial apoptosome leading to activation of the initiator caspase-9, followed by activation of the effector caspases 3, 6 and 7. This pathway can be amplified by caspase-8-or -3-mediated cleavage of Bid to tBid that then activates Bax. Apart from mediating this auto-amplification loop, Bid connects the extrinsic to the intrinsic apoptosis pathway. DD, death domain; DED, death-effector domain; CARD, caspase-recruitment domain. Bax caspases), AIF (apoptosis-inducing factor), the serine protease Omi/Htr2 and others, such as endonuclease G, into the cytosol [4] . This, and changes in mitochondrial membrane permeability leading to efflux of H + , Ca 2+ and other ion fluxes that cause acidification of the cytosol and loss of the mitochondrial membrane potential, are early events during apoptosis. Cytochrome c forms a complex with the adaptor protein Apaf-1 (apoptotic protease-activating factor 1), dATP or ATP, and pro-caspase-9 in the cytosol. Upon formation of this 'apoptosome', the caspase-9 zymogen is processed and triggers the cleavage and activation of effector caspases, ultimately leading to cell death. These events are counteracted by Bcl-2 and its anti-apoptotic homologues, such as Bcl-x L [5] . Both Bcl-2 and Bcl-x L inhibit the release of cytochrome c and other mitochondrial events during apoptosis.
Interestingly, some of these Bcl-2-homologous proteins do not inhibit apoptosis, but on the contrary, promote cell death. The Bcl-2-associated x protein Bax was the first Bcl-2 homologue to be identified that had apoptosis-promoting properties. Bax is a direct activator of mitochondria that triggers the release of cytochrome c [6] and other mitochondrial events, such as the breakdown of the mitochondrial membrane potential and the release of pro-apoptotic factors.
Structure, function and protein interactions
The search for bcl-2-interacting genes by means of yeast two-hybrid screens and for bcl-2-homologous genes by PCR strategies based on the use of degenerate primers rapidly yielded a large number of bcl-2-homologous genes. A list and classification based on structure and function of the growing family of anti-and pro-apoptotic bcl-2 homologues is given in Figure 2 . Such structural and functional analyses showed that the growing family of bcl-2-homologous genes can be divided into at least three distinct subfamilies: the Bcl-2 and the Bax subfamily, and the BH3-only proteins (where BH means Bcl-2 homology). DNA and protein sequence alignments identified five homologous conserved regions in Bcl-2 family members that are critical for function and protein-protein interaction: four Bcl-2-homology regions, BH1 (amino acids 136-155), BH2 (187-202), BH3 (93-107) and BH4 , plus a transmembrane region. All cellular anti-apoptotic Bcl-2 homologues carry a BH1, a BH2 and a BH4 domain. In contrast, the C. elegans homologues and related proteins found in pathogenic viruses show high sequence homology only in the BH1 and BH2 domains, whereas functions of the BH4 (and BH3) domains appear to be carried out by non-homologous regions of the proteins. Homology of human Bcl-2 homologues with C. elegans proteins demonstrates the evolutionary conservation and helped to identify functionally relevant domains. Moreover, the presence of anti-apoptotic bcl-2-homologous genes in pathogenic viruses delineates the functional relevance of apoptosis in the control of virus infection and limitation of viral replication.
Notably, Bcl-2 homologues can interact with each other. These interactions occur through the BH1, the BH2 and, most importantly, the BH3 domain. Deletion of the BH1, BH2 or BH4 domains of Bcl-2 impairs its ability to suppress cell death in mammalian cells and prevents homodimerization of these mutant proteins, although they can still bind to the wild-type Bcl-2 protein. In contrast, all pro-apoptotic family members contain a highly conserved BH3 domain.
Further analyses revealed that the apoptosis-promoting Bcl-2 family members can be organized into two subfamilies: (i) the Bax homologues, including Bax, Bak and Bok/Mtd, and (ii) a subfamily that includes Bad, Bid, Bim, Bmf, Hrk, Nbk, Bnip3, Noxa and Puma [7] . These homologues carry only one of the signature domains of Bcl-2, the BH3 domain, and are therefore designated BH3-only proteins. Interestingly, mutation of the BH3 domain destroys the apoptotic function of Bcl-2 homologues. In addition, cell-permeant peptides derived from Bax or other pro-apoptotic Bcl-2 homologues antagonize Bcl-2-and Bcl-x L -mediated protection from apoptosis. Surprisingly, exchanging the
Figure 2. Structural and functional classification of Bcl-2 family proteins
Structural analyses identified five homologous regions in Bcl-2 family members. These are the BH domains BH1, BH2 (light-blue boxes), BH3 (dark blue) and BH4 (white), and the transmembrane domain (mid-blue boxes). Anti-apoptotic viral and C. elegans Bcl-2 homologues do not carry a BH3 and BH4 domain. The BH3 domain in the pro-apoptotic members binds to the hydrophobic pocket formed by the BH1-BH3 domains of the survival factors. The C-terminal hydrophobic domain mediates anchoring of some of the proteins in intracellular membranes. Structure-function analyses identified three distinct subfamilies: the anti-apoptotic Bcl-2 homologues, the proapoptotic multidomain Bax homologues and the subfamily of BH3-only proteins. The latter act as indirect mediators of cell death through interaction with the Bax-homologous multidomain proapoptotic proteins. A number of additional pro-apoptotic multidomain proteins show distinct structural and functional characteristics, such as Bcl-G L , or carry a BH4 domain, such as Bcl-x S , and were therefore not yet assigned to a distinct pro-apoptotic subfamily. BH3 domains between Bcl-2 and Bax did not impair the propensity of Bax to induce apoptosis. In fact, Bcl-2 may be converted to a pro-apoptotic molecule with Bax-like functions during apoptosis. This occurs through proteolysis of Bcl-2 by caspase-3 that eliminates the N-terminal part containing the BH4 and the loop domains. Such cleavage-resistant mutants of Bcl-2 mediated increased protection from apoptosis. Thus cleavage of Bcl-2 by caspases may ensure the inevitability of cell death. In addition, these data indicate that other parts of the Bcl-2 molecule and its anti-apoptotic homologues apart from the BH1-BH3 domains are involved in mediating their death-inhibitory properties. Analyses of three-dimensional solution structures and functional analyses of deletion mutants revealed that this death-inhibitory function must be located in the N-terminal regions of the protein containing the BH4 domain. The conserved BH4 domain is found in all anti-apoptotic Bcl-2 homologues.
Previous reports have suggested at least two distinct mechanisms for inhibition of apoptosis: Bcl-2 and Bcl-x L might inhibit either the formation of the cytochrome c/Apaf-1/caspase-9 apoptosome complex by preventing cytochrome c release from mitochondria or they might interfere with the function of this apoptosome through a direct interaction of Bcl-2 or Bcl-x L with Apaf-1.
The three-dimensional solution structure of the full-length Bax protein has been solved by NMR [8] . The Bax structure shows a high similarity to the overall conformation of the four other Bcl-2 family proteins for which structural information is available, the anti-apoptotic proteins Bcl-w, Bcl-x L and Kaposi's sarcoma virus v-Bcl-2, and the pro-apoptotic BH3-only protein Bid. The proteins contain central hydrophobic helices (␣5 and ␣6) surrounded by amphipathic helices with some (minor) structural differences in the v-Bcl-2. The BH1, BH2 and BH3 domains are located in close proximity on the surface of the protein and form a hydrophobic groove that also contains the BH3 domain and appears to represent the binding site for other Bcl-2 family members [9] . Structural analyses indicate that activation of Bax homologues results in conformational changes that expose the hydrophobic transmembrane domain and thereby trigger insertion into membranes. This coincides with exposure of the BH3-domain-containing groove that would then allow homoand hetero-philic interactions, i.e. oligomerization and channel formation in the case of Bax and Bak.
Some reports suggested that the BH4 domain is critical for binding of Bclx L to the apoptosome. It was postulated that Bcl-x L (and homologues) would prevent apoptosis by interfering with the activation of pro-caspase-9 in the complex formed with Apaf-1 and cytochrome c. The physical interaction of Bcl-x L is, however, rather weak and no physical interaction was found in coimmunoprecipitation studies with anti-apoptotic Bcl-2 homologues (Bcl-2, Bcl-x L , Bcl-w, A1, Mcl-1 or Boo), viral Bcl-2 mimics (adenovirus E1B 19K and Epstein-Barr virus BHRF-1) or with two pro-apoptotic relatives (Bax and Bim) [10] . Furthermore, recombinant Bcl-x L inhibited mitochondrial activation and cytochrome release when added to isolated mitochondria in a cell-free system, but failed to inhibit caspase activation induced by exogenous cytochrome c and dATP in cytosolic extracts, i.e. occuring downstream of the mitochondria [11] .
Subcellular localization, redistribution and channel formation
Novel insights into the mode of action of Bcl-2 family proteins also came from studies investigating their subcellular-distribution patterns. Bcl-2 was shown early on to locate to the outer mitochondrial membrane. Bcl-2 is also found at the nuclear and the ER (endoplasmic reticulum) membranes facing the cytosol. In contrast, Bcl-x L was shown recently to localize preferentially to the mitochondria. The pro-apoptotic Bcl-2 homologues Bax and Bak may localize both to the ER and the mitochondria.
The subcellular distribution of splice variants of these proteins may differ. Bcl-2 can occur as Bcl-2␣ or Bcl-2␤, two alternatively spliced forms that differ solely in their C-termini. The finding that Bcl-2␣ is active and membranebound, but that Bcl-2␤ is inactive and cytosolic, indicates that the C-terminus and the membrane localization contributes to the survival activity of Bcl-2␣ [12] . Similarly, the short splice variant of Bcl-x, Bcl-x S , lacks a transmembrane domain and is found in the cytosol whereas Bcl-x L is found in both the cytosol and the outer mitochondrial membrane in healthy, non-apoptotic cells. During apoptosis, Bcl-x L redistributes quantitatively to the mitochondria. Thus the membrane localization seems to be critical for the function of anti-apoptotic Bcl-2 homologues. Likewise, Bax is found as a monomer in the cytosol of most normal healthy tissues, which indicates that the protein is kept in an inactive form in the cells [13] . During induction of the mitochondrial pathway, Bax and Bak become activated and undergo a conformational switch in the Nterminus and the C-terminus that results in redistribution of Bax to the mitochondria [14] . Activation of Bax results in insertion of Bax into the outer mitochondrial membrane. Bax translocation to the mitochondria coincides with oligomerization of Bax to multimeric complexes. Likewise, recombinant Bax oligomerizes and forms channels in artificial liposomal membranes [15] . Such Bax oligomers possess channel-forming properties that are associated with ion fluxes and consecutive loss of the mitochondrial membrane potential. In contrast, Bak resides constitutively in the mitochondrial membrane and the ER (see below), where it oligomerizes upon activation [16] .
Channel formation by Bax or Bak oligomers has been proposed to be responsible for the release of cytochrome c from the mitochondria. In fact, image analysis of the interaction of the Bax with membrane bilayers shows the presence of toroidal-shaped pores by means of atomic force microscopy. These pores are large enough to allow for passage of proteins such as cytochrome c from the intermembrane space of mitochondria.
Nevertheless, the release of cytochrome c release through Bax or Bak channels is discussed controversially. Activation of other channels, such as the permeability transition pore, has been implicated in the release of cytochrome c and ion fluxes induced by Bax and Bak. This channel is formed from a complex of the VDAC (voltage-dependent anion channel), the ANT (adenine nucleotide translocase) and cyclophilin-D at contact sites between the mitochondrial outer and inner membranes. There is some evidence that this complex can recruit a number of other proteins, including Bax [17] . Thus Bax and other Bcl-2 homologues have been implicated as regulators of the VDAC/ANT permeability pore. There is, however, also evidence that Bax oligomers do, at best, bind only weakly to VDAC channels.
The situation for other pro-apoptotic factors released from mitochondria is far less clear. Recent data suggest that Smac is also released through a Bax/Bak-dependent mechanism while others observed temporary dissociation of cytochrome c and Smac release, indicating that distinct mechanisms might be involved. Nevertheless, pro-apoptotic factors may also be released during late mitochondrial activation, when ion fluxes through the permeability transition pore formed by VDAC proteins in the outer and ANT in the inner mitochondrial membrane (and so-far-undefined 'megapores') have led to swelling and fragmentation of the mitochondria, a mechanism that can be prevented by Bcl-x L . Thus AIF, and possibly other factors appear, to be released through mechanisms that operate downstream of cytochrome c and are independent from Bax [18] .
Recently, an interaction between Bax and Drp1 (dynamin-related protein 1) was described that suggests a completely different view of how Bcl-2 and its homologues regulate mitochondrial apoptosis [19] : clustering of mitochondria around the nucleus and mitochondrial fragmentation is a typical feature of cells undergoing apoptosis. Interestingly, Bax translocates to discrete foci on mitochondria during the initial stages of apoptosis, which subsequently become mitochondrial scission sites. Surprisingly, the dynamin-related GTPase Drp1 and the mitofusin GTPase Mfn2, but not other proteins implicated in the regulation of mitochondrial morphology and physiological fission and fusion events, co-localize with Bax in these foci. Mfn2 is an outer mitochondrial membrane protein with N-terminal and C-terminal domains exposed towards the cytosol. Interestingly, Mfn2 over-expression can trigger perinuclear clustering of mitochondria, a phenomenon that is frequently observed during apoptosis. Co-expression of Mfn2 with a dominant-interfering mutant Drp1 proposed to block mitochondrial fission results in long mitochondrial filaments and networks. Moreover, a dominant-negative mutant of Drp1 inhibited apoptotic scission of mitochondria, but did not inhibit Bax translocation or coalescence into foci. This indicates that Bax participates in apoptotic fragmentation of mitochondria through interaction with Drp1/Mfn2. The question whether this mechanism is the real cause for triggering the mitochondrial apoptosis signalling events remains, however, to be clarified. A compilation of the various models and levels of regulation is provided in Figure 3 .
Finally, Bcl-2 homologues might act in an organelle-specific manner [20] . Whereas Bcl-2 is distributed in a rather promiscuous manner to cellular organelle membranes facing the cytosol, activated Bcl-x L preferentially localizes to mitochondria. Likewise, the BH3-only protein Nbk (natural born killer; or Bik, Bcl-2-interacting killer) distributes to the ER and not to the mitochondria, indicating that Nbk triggers Bax activation in the mitochondria through an indirect mechanism. This view is supported by the observation that Nbk induces apoptosis in a Bax-dependent manner, but fails to directly bind to Bax [21] . Moreover, Bak localizes to the ER where it regulates Ca 2+ efflux that might trigger secondary activation of mitochondria following ER stress responses. Likewise, Bcl-2 expression in the ER inhibits Ca 2+ release from the ER calcium pool and inhibits apoptosis upon various stimuli [22] . This indicates a broader role for the ER in apoptosis control than previously imagined that might equal that of the mitochondria [20] . Last, but not least, given their distinct roles in the ER and the mitochondria, there is accumulating evidence that Bax and Bak might not be fully redundant in regulating apoptosis. In fact, the BH3-only protein Nbk triggers apoptosis in an entirely Bax-dependent, but Bak-independent, manner [21] . This adds a higher degree of specificity and complexity to the previously suggested interchangeability of Bcl-2 homologues in the regulation of apoptosis.
BH3-only proteins as sensors that mediate activation of Bax and Bak
Recently, it was demonstrated that the pro-apoptotic activities of certain BH3-only proteins essentially depends on the presence of either Bax or Bak (reviewed in [7] ). This finding suggests that some BH3-only proteins can promote apoptosis by two mutually non-exclusive mechanisms: by directly inactivating pro-survival Bcl-2-proteins or through direct or indirect modification of Bax-like molecules. BH3-only proteins may function as death sensors and their pro-apoptotic activity is subject to stringent control (Figure 4 ). For example, Noxa, Puma, Nbk and Hrk are transcriptionally induced by p53 upon stress conditions. Many other BH3-only proteins are present in healthy cells in a dormant form and are activated upon post-translational modifications, such as phosphorylation of Bad or Nbk. Bim and Bmf represent two BH3-only proteins that are regulated by sequestration to cytoskeletal structures. During apoptosis mediated upon ligation of death receptors, the BH3-only protein Bid is proteolytically cleaved by caspase-8 to a pro-apoptotic form (tBid) from an inactive form. tBid appears to interact physically with Bax to mediate a conformational change in the Bax N-terminus [23] . This event triggers insertion of cytosolic Bax into the outer mitochondrial membrane [14] . Thus Bid links death-receptor signalling to the mitochondrial pathway. Interestingly, Bid cleavage can occur in a death receptor-independent manner downstream of the mitochondria through a caspase-3-and -8-dependent mechanism [24] . Thus caspase-3, caspase-8 and Bid cleavage mediate a positive-feedback loop that is required for full cytochrome c release during anti-cancer drug-induced apoptosis [25] . Other reports found that Bid can also be cleaved by non-caspase proteases, especially granzyme B and lysosomal proteases, e.g. the cathepsins. Apart from mediating the above-mentioned amplification loop, Bid cleavage by lysosomal proteases was implicated in cross-talk between lysosomes and mitochondria during apoptosis.
Unlike several other members of the BH3-only family, Nbk/Bik triggers apoptosis in an entirely Bax-dependent manner [21] . Ectopic expression of Nbk impaired the tumorigenicity in a SCID (severe combined inmmunodeficient) mouse xenotransplant model and promoted drug-induced apoptosis, indicating that Nbk acts in the DNA-damage-response pathway [26] . It has been proposed that the activity of the BH3-only protein Nbk is controlled by phosphorylation. Opposite to the case of Bad, phosphorylation increases the pro-apoptotic potency of Bik through a presently unknown mechanism that does not affect its affinity for anti-apoptotic Bcl-2 members.
Like other BH3-only proteins, including Nbk, the BH3-only protein Bad interacts via its BH3 domain with Bcl-x L . This may indicate that anti-apoptotic Bcl-2 homologues serve as a 'sink' that sequesters BH3-only proteins either in the cytosol or at membranes. In fact, Bad is inactivated upon phosphorylation of Ser-155 within the BH3 domain through the anti-apoptotic Akt kinase [27] . This leads to sequestration of the phosphorylated Bad in the cytosol through binding to 14-3-3 proteins. The sequestration of Bad, in turn, was shown to enhance the anti-apoptotic properties of Bcl-x L . This appears to occur through phosphorylation and binding of Bad to 14-3-3 proteins instead of binding of the unphosphorylated Bad to Bcl-x L . Thus phosphorylation of Bad impairs its pro-apoptotic potency. Finally, Bcl-2 is subject to post-translational modification during apoptosis, mainly upon exposure of cells to microtubule toxins such as vinca alkaloids and taxanes that trigger unco-ordinated microtubule polymerization. Hyperphosphorylation of Bcl-2 mediated by Paclitaxel and other microtubule-active drugs is strictly dependent on targeting microtubules that in turn cause mitotic arrest. In addition to Ser-70, microtubule-active agents promote phosphorylation of Ser-87 and Thr-69, thereby inactivating Bcl-2. This multisite phosphorylation of the Bcl-2 loop domain is followed by cell death. In contrast, in cytokine-dependent cell lines, cytokines mediate phosphorylation of Bcl-2 at Ser-70 that prevents apoptosis [28] . Thus functions of Bcl-2 family proteins are differentially regulated by serine/threonine phosphorylation and this seems to be of special importance at the level of the BH3-only proteins.
Bcl-2 family proteins as drug targets in cancer
Over-expression of Bcl-2, Bcl-x L or other anti-apoptotic homologues or loss of Bax and Bak is a common feature of human tumours. Apart from being involved in tumorigenesis where deregulation of Bcl-2 homologues is required to counteract pro-apoptotic properties of oncogenes, expression and mutation analyses in human tumours revealed that over-expression of anti-apoptotic Bcl-2 family members or loss of Bax homologues is associated with the acquisition of clinical resistance to anti-cancer therapies [29, 30] . Interestingly, clinical data show that the loss of pro-apoptotic homologues, rather than the high expression of anti-apoptotic homologues is associated with resistance to anti-cancer therapy [31, 32] .
The manipulation of apoptosis for therapeutic purposes is receiving considerable attention from the pharmaceutical industry. In fact, a variety of reports demonstrated that the enforced expression of pro-apoptotic Bcl-2 homologues facilitates apoptosis, decreases tumorigenicity, and overcomes resistance to chemotherapy and ionizing irradiation [26] . This suggested that Bcl-2 proteins are putative targets for development of novel anti-tumour agents (reviewed in [33] ). Based on structural and functional data, antagonists of Bcl-2 were developed based on different strategies. Antisense oligonucleotides against Bcl-2 are currently evaluated in phase III multi-centre clinical trials as anti-cancer agents in malignant melanoma, follicular lymphoma and multiple myeloma. Results from phase I/II trials showed good activity and tumour regression in some patients.
Nevertheless, the Bcl-2 family consists of proteins with redundant functions. Thus targeting multiple Bcl-2 homologues at the same time appears to be more promising. This was achieved in vitro by the use of cell-permeant BH3-only domain-derived peptides that potently trigger apoptosis. Recently, a number of small molecules were developed as BH3 mimics that bind to the BH3-containing cleft in Bcl-2 or Bcl-x L . These small-molecule inhibitors specifically block the BH3-domain-mediated heterodimerization between Bcl-2 family members in vitro and in vivo and consequently induce apoptosis (reviewed in [33] ). At least one of these Bcl-2-inhibitory compounds acts through the activation of Bax. Surprisingly, loss of the pro-apoptotic Bax or overexpression of Bcl-2 results in a selective resistance against some, but not all, cancer therapeutics, thereby indicating that some, but not all, cancer therapies depend on Bax or Bcl-2 to execute cell death [34] . This, together with the frequent inactivation of Bax and/or Bak in cancer, indicates that Bcl-2-targeting agents, despite their apparent potency, might not yet be the 'magic bullets' urgently required to overcome resistance to therapy in cancer and to improve cure rates. Further insights into the structural differences between various Bcl-2 homologues and their BH3 domains should help to add a higher degree of specificity to such 'molecular' therapies and to avoid undesired toxicities.
Conclusions
Significant progress has been made in our understanding of how Bcl-2 proteins regulate apoptosis. Apart from regulating the mitochondrial and ER pathways of apoptosis, members of the Bcl-2 family functionally interconnect apoptosis pathways to converge at the mitochondria. Thus it is now clear that the subfamily of BH3-only proteins acts as sensor to trigger mitochondrial activation and amplification of the apoptotic signalling as a consequence of various upstream signals originating at the membrane, the nucleus, the cytoskeleton and other cellular compartments, including the ER. In this vein, the elucidation of three-dimensional solution structures of pro-and antiapoptotic Bcl-2 proteins was a significant step towards a therapeutic manipulation of apoptosis signalling and the development of small-molecule inhibitors of Bcl-2 that should help to improve treatment of diseases with disturbed apoptosis signalling, such as cancer or autoimmunity. 
Summary

• Structural and functional analyses allow a classification of
